{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:28:33Z","timestamp":1780824513385,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"R21","award":["5R21AI115082-02"],"award-info":[{"award-number":["5R21AI115082-02"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.antiviral.2018.10.025","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T05:38:17Z","timestamp":1541223497000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Novel amodiaquine derivatives potently inhibit Ebola virus infection"],"prefix":"10.1016","volume":"160","author":[{"given":"Yasuteru","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-0662","authenticated-orcid":false,"given":"Norikazu","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-2892","authenticated-orcid":false,"given":"Robert A.","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.10.025_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/2040206617740303","article-title":"Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors","volume":"25","author":"Baba","year":"2017","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.10.025_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2018.10.025_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0163-7258(01)00140-1","article-title":"Artemisinin and its derivatives: an important new class of antimalarial agents","volume":"90","author":"Balint","year":"2001","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2018.10.025_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of Ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.025_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2014.03.014","article-title":"Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity","volume":"106","author":"Boonyasuppayakorn","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.025_bib7","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1021\/jm980146x","article-title":"Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines","volume":"41","author":"De","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.10.025_bib8","doi-asserted-by":"crossref","first-page":"e1001997","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib9","doi-asserted-by":"crossref","first-page":"e0162199","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental treatment of Ebola virus disease with brincidofovir","volume":"11","author":"Dunning","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.10.025_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acsinfecdis.5b00053","article-title":"High-throughput minigenome system for identifying small-molecule inhibitors of Ebola virus replication","volume":"1","author":"Edwards","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.025_bib11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.7217.1","article-title":"Machine learning models identify molecules active against the Ebola virus in vitro","volume":"4","author":"Ekins","year":"2015","journal-title":"F1000Research"},{"key":"10.1016\/j.antiviral.2018.10.025_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504605","article-title":"Effect of artesunate-amodiaquine on mortality related to Ebola virus disease","volume":"374","author":"Gignoux","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jmv.25031","article-title":"The antimalarial drug amodiaquine possesses anti-ZIKA virus activities","volume":"90","author":"Han","year":"2018","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0166-6851(96)02655-2","article-title":"Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine","volume":"80","author":"Hawley","year":"1996","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.antiviral.2018.10.025_bib16","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/AAC.00675-10","article-title":"4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses","volume":"55","author":"Hocart","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.025_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-med-052915-015604","article-title":"Ebola: anatomy of an epidemic","volume":"68","author":"Lo","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060579","article-title":"A systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2018.10.025_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.10.025_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/path.4456","article-title":"Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses","volume":"235","author":"Martines","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2015.10.010","article-title":"The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus","volume":"125","author":"McMullan","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.025_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/JVI.73.3.2333-2342.1999","article-title":"Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems","volume":"73","author":"Muhlberger","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib26","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1021\/jm030796n","article-title":"Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials","volume":"46","author":"O'Neill","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.10.025_bib27","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1128\/AAC.02814-14","article-title":"In vitro efficacy of brincidofovir against variola virus","volume":"58","author":"Olson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.025_bib28","first-page":"115","article-title":"Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review","volume":"42","author":"Parhizgar","year":"2017","journal-title":"Iran. J. Med. Sci."},{"key":"10.1016\/j.antiviral.2018.10.025_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.025_bib30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","author":"PREVAIL II Writing Group","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib31","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.1258758","article-title":"Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment","volume":"347","author":"Sakurai","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2018.10.025_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00204-009-0436-9","article-title":"Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice","volume":"83","author":"Shimizu","year":"2009","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.antiviral.2018.10.025_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2017.11.016","article-title":"Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection","volume":"149","author":"Shtanko","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.10.025_bib34","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib36","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.45.5.1450-1455.2001","article-title":"Inhibition of intramacrophage growth of Penicillium marneffei by 4-aminoquinolines","volume":"45","author":"Taramelli","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.10.025_bib37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.10.025_bib38","author":"World Health Organization"},{"key":"10.1016\/j.antiviral.2018.10.025_bib39","doi-asserted-by":"crossref","first-page":"13476","DOI":"10.1038\/srep13476","article-title":"Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting","volume":"5","author":"Zilbermintz","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218305357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:46Z","timestamp":1759062586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218305357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"alternative-id":["S0166354218305357"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.025","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel amodiaquine derivatives potently inhibit Ebola virus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}